VIVIMEDLAB Share Price | Vivimed Labs Ltd Stock Analysis & Recommendation

Q: Why is Vivimed Labs Ltd falling/rising?

As of 09-Jun, Vivimed Labs Ltd's stock price is currently at 6.14, reflecting a decrease of 0.05, or 0.81%. The stock has experienced a notable decline over various periods, including a 5.54% drop over the past week and a significant 10.76% decrease over the past month. Year-to-date, the stock is down 65.17%, which is considerably worse than the 13.26% decline of the Sensex during the same timeframe.Despite today's performance showing a slight outperformance against the sector by 0.32% and a trend reversal after two consecutive days of decline, the stock is still trading below all key moving averages (5-day, 20-day, 50-day, 100-day, and 200-day). This indicates a bearish trend overall. However, there has been a rise in investor participation, with delivery volume increasing by 11.59% compared to the 5-day average, suggesting some interest from investors.In summary, while there are some positive indicators such as increased trading volume and a minor outperformance against the sector today, the overall trend remains negative due to significant declines over longer periods and the stock's position relative to moving averages.

Q: Should I buy, sell or hold Vivimed Labs Ltd?

Given the current financial situation of Vivimed Labs Ltd, it is advisable to consider a strong sell position. The company is burdened with a high debt load, reflected in a Debt-Equity Ratio of 9.51 times, which indicates significant leverage and weak long-term fundamental strength. Additionally, the negative Debt to EBITDA ratio of -2.02 times suggests a low ability to service its debt obligations.The company has also reported losses, leading to a negative Return on Equity (ROE), which further underscores its financial instability. Recent results show a negative EBITDA of Rs. -11.15 crore, and profits have drastically fallen by 386% over the past year. This performance, combined with the stock's risky trading status compared to its historical valuations, raises concerns about its viability.Furthermore, the majority of shareholders are non-institutional, which may add to the volatility and risk associated with the stock. Given these factors, holding or buying shares in Vivimed Labs Ltd could expose you to significant financial risk. It would be prudent to consider selling your position in the company.

Q: When is the next results date for Vivimed Labs Ltd?

The next results date for Vivimed Labs Ltd is scheduled for 30 May 2026.

Results Declared: Vivimed Labs. has declared results on 30 May 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

29.94 k (-43.38%) Volume

Shareholding (Mar 2026)

FII

1.64%

Held by 5 FIIs

DII

0.12%

Held by 0 DIIs

Promoter

7.57%

Which are the latest news on Vivimed Labs.?

10-Jun-2026

Vivimed Labs Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight
Vivimed Labs Ltd is Rated Strong Sell

Why is Vivimed Labs Ltd falling/rising?

09-Jun-2026

As of 09-Jun, Vivimed Labs Ltd's stock price is at 6.14, down 0.81%. Despite a slight outperformance today and increased trading volume, the stock shows a bearish trend with significant declines over the past month and year-to-date.

View full answer

Should I buy, sell or hold Vivimed Labs Ltd?

31-May-2026

When is the next results date for Vivimed Labs Ltd?

27-May-2026

The next results date for Vivimed Labs Ltd is 30 May 2026.

View full answer

Compare Vivimed Labs. with Similar Stocks

Dr Reddy's Labs Guj. Inject(Ker)Torrent Pharma

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With HIgh Debt (Debt-Equity Ratio at 9.51 times)- the company has a Weak Long Term Fundamental Strength

Low ability to service debt as the company has a high Debt to EBITDA ratio of -2.02 times
The company has reported losses. Due to this company has reported negative ROE

Flat results in Dec 25

Risky - Negative EBITDA

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Drugs

Market cap

INR 50 Cr (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

9.51

Return on Equity

-833.41%

Price to Book

1.32

Revenue and Profits:

Net Sales:

16 Cr

(Quarterly Results - Dec 2025)

Net Profit:

-17 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-13.09%

6 Months

0.0%

1 Year

0.0%

2 Years

0.0%

3 Years

3.6%

4 Years

-52.89%

5 Years

-79.32%

Latest dividend: 0.4 per share ex-dividend date: Sep-19-2018

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Vivimed Labs Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight

At Rs 6.08, sellers were still queuing — but there were no buyers willing to take the other side. Vivimed Labs Ltd locked at its lower circuit of 5% on 8 Jun 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance between supply and demand.

Read full news article

Vivimed Labs Ltd is Rated Strong Sell

Vivimed Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 June 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Vivimed Labs Ltd Locks at Upper Circuit With 1.4% Gain — Buyers Queue, Sellers Absent

At Rs 6.77, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vivimed Labs Ltd locked at its upper circuit of 5% on 29 May 2026, with buyers queuing and no sellers willing to part with shares.

Read full news article

Announcements

Board Meeting Postponed

30-May-2026 | Source : BSE

Board meeting Postponed

Update on board meeting

26-May-2026 | Source : BSE

The Board Meeting to be held on 28/05/2026 has been revised to 30/05/2026 The Board Meeting to be held on 28/05/2026 has been revised to 30/05/2026

Compliances-Reg.24(A)-Annual Secretarial Compliance

19-May-2026 | Source : BSE

annual secretarial compliance report

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

Vivimed Labs Ltd has declared 20% dividend, ex-date: 19 Sep 18

SPLITS

Vivimed Labs Ltd has announced 2:10 stock split, ex-date: 06 Apr 16

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-53.40%

EBIT Growth (5y)

-421.22%

EBIT to Interest (avg)

-1.77

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

9.51

Sales to Capital Employed (avg)

0.80

Tax Ratio

0.64%

Dividend Payout Ratio

Pledged Shares

15.18%

Institutional Holding

1.76%

ROCE (avg)

-0.76%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.32

EV to EBIT

-13.33

EV to EBITDA

-38.27

EV to Capital Employed

1.03

EV to Sales

3.93

PEG Ratio

Dividend Yield

ROCE (Latest)

-71.39%

ROE (Latest)

-833.41%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Non Institution

Pledged Promoter Holdings

15.1806

Mutual Funds

Held by 0 Schemes

FIIs

Held by 5 FIIs (1.64%)

Promoter with highest holding

Varalwar Sandeep (2.81%)

Highest Public shareholder

Kitara Piin 1102 (9.37%)

Individual Investors Holdings

68.75%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11.63",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.22",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.94",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-16.57",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-96.47%",
          "val2": "NA%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'22",
        "Sep'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "94.33",
          "val2": "119.63",
          "chgp": "-21.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.88",
          "val2": "0.31",
          "chgp": "-5,867.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "18.17",
          "val2": "18.12",
          "chgp": "0.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.23",
          "val2": "-25.63",
          "chgp": "-72.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-18.95%",
          "val2": "0.26%",
          "chgp": "-19.21%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "150.07",
          "val2": "176.15",
          "chgp": "-14.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.01",
          "val2": "-6.98",
          "chgp": "-229.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "27.39",
          "val2": "29.70",
          "chgp": "-7.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-62.54",
          "val2": "-49.31",
          "chgp": "-26.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-15.33%",
          "val2": "-3.96%",
          "chgp": "-11.37%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -37.86% vs -21.15% in Mar 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 90.27% vs -385.63% in Mar 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "116.27",
          "val2": "187.10",
          "chgp": "-37.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.05",
          "val2": "-187.30",
          "chgp": "93.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.95",
          "val2": "35.90",
          "chgp": "-91.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-31.96",
          "val2": "-328.53",
          "chgp": "90.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-11.22%",
          "val2": "-100.11%",
          "chgp": "88.89%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ

Dec'25

Change(%)

Net Sales

11.63

Operating Profit (PBDIT) excl Other Income

-11.22

Interest

0.94

Exceptional Items

0.00

Standalone Net Profit

-16.57

Operating Profit Margin (Excl OI)

-96.47%

NA%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Quarterly Results

Half Yearly Results Snapshot (Consolidated) - Sep'22

Sep'22

Sep'21

Change(%)

Net Sales

94.33

119.63

-21.15%

Operating Profit (PBDIT) excl Other Income

-17.88

0.31

-5,867.74%

Interest

18.17

18.12

0.28%

Exceptional Items

0.00

Consolidate Net Profit

-44.23

-25.63

-72.57%

Operating Profit Margin (Excl OI)

-18.95%

0.26%

-19.21%

Values in Rs Cr.

Compare with Peers

Net Sales

Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021

Consolidated Net Profit

Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021

All Half Yearly Results

Nine Monthly Results Snapshot (Consolidated) - Dec'22

Dec'22

Dec'21

Change(%)

Net Sales

150.07

176.15

-14.81%

Operating Profit (PBDIT) excl Other Income

-23.01

-6.98

-229.66%

Interest

27.39

29.70

-7.78%

Exceptional Items

0.00

Consolidate Net Profit

-62.54

-49.31

-26.83%

Operating Profit Margin (Excl OI)

-15.33%

-3.96%

-11.37%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021

Consolidated Net Profit

YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021

All Nine Monthly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'23

Change(%)

Net Sales

116.27

187.10

-37.86%

Operating Profit (PBDIT) excl Other Income

-13.05

-187.30

93.03%

Interest

2.95

35.90

-91.78%

Exceptional Items

0.00

Consolidate Net Profit

-31.96

-328.53

90.27%

Operating Profit Margin (Excl OI)

-11.22%

-100.11%

88.89%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is -37.86% vs -21.15% in Mar 2023

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 90.27% vs -385.63% in Mar 2023

All Annual Results

Company CV

About Vivimed Labs Ltd

Vivimed Labs Ltd

Micro Cap

Pharmaceuticals & Drugs

Vivimed Labs Ltd is engaged in manufacturing of Specialty Chemicals (mainly used in Personal Care and Cosmetic Industry), Pharmaceuticals, API's and Formulations. The company has strong presence in the areas of Health & Personal Care, Contract Research and Manufacturing. The company has four subsidiary companies, namely Creative Health Care Pvt Ltd, Vivimed Holdings Ltd (Hong Kong), Vivimed Labs Europe Ltd (UK) and Vivimed Labs USA Inc.

Company Coordinates

Company Details

Plot No 78-A, Kolhar Industrial Area Bidar Karnataka : 585403

Tel: 91-8482-232045

http://www.vivimedlabs.com

yugandhar.kopparthi@vivimeslabs.com

Registrar Details

Aarthi Consultants Pvt Ltd, 1-2-285 , Domalaguda, Hyderabad